

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
17 February 2022 (17.02.2022)



(10) International Publication Number

WO 2022/036204 A1

(51) International Patent Classification:

A61K 31/50 (2006.01) *C07D 237/30* (2006.01)
A61K 31/5025 (2006.01) *C07D 237/32* (2006.01)
C07D 237/26 (2006.01)

(21) International Application Number:

PCT/US2021/045924

(22) International Filing Date:

13 August 2021 (13.08.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/066,074 14 August 2020 (14.08.2020) US
63/151,600 19 February 2021 (19.02.2021) US

(71) Applicant: **DENALI THERAPEUTICS INC.** [US/US];
161 Oyster Point Blvd., South San Francisco, California
94080 (US).

(72) Inventors: **CRAIG, II, Robert A.**; c/o Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080 (US). **DE VICENTE FIDALGO, Javier**; c/o Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080 (US). **ESTRADA, Anthony A.**; c/o Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080 (US). **FOX, Brian M.**; c/o Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080 (US). **HU, Cheng**; c/o Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080 (US). **LEXA, Katrina W.**; c/o Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080 (US). **NILEWSKI, Lizanne G.**; c/o Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080 (US). **OSIPOV, Maksim**; c/o Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080 (US). **THOTTUMKARA, Arun**; c/o Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080 (US). **BAGDASARIAN, Alex L.**; c/o Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080 (US). **HUFFMAN, Benjamin J.**; c/o Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080 (US).

(74) Agent: **TANNER, Lorna L.** et al.; SHEPPARD MULLIN RICHTER & HAMPTON LLP, 650 Town Center Drive, 10th Floor, Costa Mesa, California 92626-1993 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,

DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: COMPOUNDS, COMPOSITIONS AND METHODS

(57) Abstract: The present disclosure relates generally to small molecule modulators of NLR Family Pyrin Domain Containing 3 (NLRP3), or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, methods of making and intermediates thereof, and methods of using thereof.

WO 2022/036204 A1